RxDoctor Payments Data

Benjamin Silverman, DO

Cardiovascular Disease · Vineland, NJNPI 1699091090

Payments from drug & device makers

$1,828in general payments, 2019–2025

Across 69 payments — averaging $26.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$397
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$392
  • Saluda Medical Americas, Inc.$194
  • Impulse Dynamics (USA) Inc.$174
  • Pfizer$152
  • E.r. Squibb & Sons, L.L.C.$119
  • plus $400 from 8 others

What the payments were for

  • Food & beverage$1,828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,828 in reported general payments places this provider in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$444,778
Medicare patients
1,210
Services billed
5,945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban446$486,446
XareltoRivaroxaban141$170,518
EntrestoSacubitril/Valsartan80$105,157
Repatha SureclickEvolocumab75$65,711
FarxigaDapagliflozin Propanediol39$42,525
JardianceEmpagliflozin14$19,681
Praluent PenAlirocumab17$18,037
BrilintaTicagrelor21$12,546
Atorvastatin Calcium778$11,391
Metoprolol Succinate495$9,003
Rosuvastatin Calcium350$7,763
VascepaIcosapent Ethyl33$5,457
Hydralazine Hcl178$4,155
Amlodipine Besylate487$3,711
Losartan Potassium268$3,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$152$486,446446 claims
Johnson & JohnsonXarelto$48$170,518141 claims
NovartisEntresto$71$105,15780 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Vineland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →